Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. The Company is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease (AD) and Diabetic Macular Edema (DME), where destructive neuroinflammation plays a central role in the disease process. The foundational science was licensed based on technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD). Therini Bio’s top-tier syndicate of life sciences investors includes the Alzheimer’s Drug Discovery Foundation, SV Health Investors’ Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Sacramento, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.therinibio.com
- HQ
- Sacramento, CA
Therini Bio, Inc. Questions
Therini Bio, Inc.'s website is http://www.therinibio.com
Therini Bio, Inc.'s LinkedIn profile is https://www.linkedin.com/company/therinibio
Therini Bio, Inc. has
10 employees.
View email and phone details for 10
employees at Therini Bio, Inc..
Therini Bio, Inc.'s industry is
Biotechnology Research
Therini Bio, Inc.'s top competitors are
Sv Health Investors,
Stealth Sf Biotech Startup,
Alector,
Bolt Biotherapeutics, Inc.,
Pathos,
Maze Therapeutics,
Prilenia,
Stylus Medicine,
Newleos Therapeutics,
Augustine Therapeutics.
Therini Bio, Inc.'s categories are Biotechnology Research
Therini Bio, Inc.'s founding year is 2016
